Last updated: October 29, 2026
Carglumic acid is a specialist orphan-drug market centered on Carbaglu, the branded product developed for hyperammonemia associated with N-acetylglutamate synthase deficiency and, in certain jurisdictions, organic acidemias. Its commercial profile combines high treatment value, very small patient populations, regulatory barriers, and growing exposure to generic competition. Recordati remains the principal commercial sponsor of Carbaglu in major markets, while product-level revenue is generally not disclosed separately in public financial reports.
What is the current market position of carglumic acid?
Carglumic acid is a small-molecule activator of carbamoyl phosphate synthetase I through restoration of N-acetylglutamate activity. It addresses a narrow segment of inherited metabolic disease rather than a broad pharmaceutical market.
| Market attribute |
Carglumic acid |
| Main branded product |
Carbaglu |
| Active ingredient |
Carglumic acid |
| Primary disease area |
Urea-cycle disorders and selected organic acidemias |
| Principal US sponsor |
Recordati Rare Diseases |
| US dosage form |
200 mg tablets; oral suspension formulation |
| FDA product |
NDA 022562 |
| Commercial model |
Orphan, high-value, low-volume |
| Generic exposure |
Increasing, depending on jurisdiction and formulation |
| Biosimilar exposure |
Not applicable because carglumic acid is a chemical drug |
| Key competitors |
Nitrogen-scavenging therapies, dietary therapy, dialysis, transplantation |
The addressable population is small. N-acetylglutamate synthase deficiency is an ultra-rare disorder, while propionic acidemia and related organic acidemias have larger but still limited populations. The market therefore depends more on diagnosis rates, treatment duration, geographic access, and reimbursement than on broad prescription growth.
What FDA approvals and indications support Carbaglu sales?
The FDA approved Carbaglu in 2010 for the treatment of acute hyperammonemia caused by N-acetylglutamate synthase deficiency. The product is used in both acute management and maintenance treatment under specialist supervision. FDA labeling also describes administration through an oral suspension prepared from tablets and delivered with water, which supports use in pediatric patients and patients unable to swallow tablets. [1]
European labeling is broader in some markets. The European Medicines Agency has authorized carglumic acid for hyperammonemia associated with N-acetylglutamate synthase deficiency and for certain organic acidemias, including propionic, methylmalonic, and isovaleric acidemias. The specific indication set varies by jurisdiction and label version. [2]
How does carglumic acid generate revenue?
Revenue is driven by four commercial variables:
- The number of diagnosed patients receiving chronic therapy.
- The proportion of patients treated during acute hyperammonemic episodes.
- Treatment duration and dose intensity.
- Net price after government rebates, hospital discounts, and specialty-pharmacy concessions.
The product has a particularly valuable emergency-use profile. An acute hyperammonemic episode can require rapid intervention, and physicians may continue therapy for maintenance in patients with recurrent risk. That creates a mixed revenue stream: episodic demand during crises and recurring demand in chronic disease.
What is the financial trajectory for carglumic acid?
Public financial reporting does not generally disclose Carbaglu revenue as a standalone line item. Recordati reports results by geographic region and business segment, including rare diseases, rather than identifying individual Carbaglu sales. This limits precision when estimating product-level revenue, growth, margins, or contribution to corporate earnings. [3]
The financial trajectory is best understood in phases.
| Period |
Commercial driver |
Financial effect |
| Initial launch period |
Orphan approval and specialist adoption |
High price, limited volume |
| Expansion period |
Greater diagnosis and broader organic-acidemia use in selected markets |
Volume growth without mass-market scale |
| Mature branded period |
Stable chronic treatment base and emergency use |
Defensible cash generation |
| Generic-entry period |
Price erosion and payer substitution |
Lower net revenue, potentially higher unit access |
| Post-generic period |
Brand retention in complex cases and supply-sensitive markets |
Residual specialty revenue |
The principal growth opportunity is not a large increase in prevalence. It is improved identification of patients through expanded newborn screening, genomic diagnosis, metabolic-specialist referral, and wider recognition of late-onset disease. The US newborn screening program identifies several urea-cycle and organic-acidemia conditions, although the precise screening panel and follow-up pathway vary by state. [4]
What limits the revenue upside?
The market has structural constraints:
- Ultra-rare disease prevalence limits patient volume.
- Diagnosis may occur only after a severe metabolic crisis.
- Treatment can be substituted or supplemented by nitrogen scavengers and dietary management.
- Hospital formularies may restrict use to metabolic specialists.
- Generic availability can reduce net price.
- Reimbursement disputes can delay therapy initiation.
- Acute-use demand is clinically important but difficult to forecast.
The product has a favorable value-per-patient profile, but its absolute market size remains constrained by epidemiology.
What patents protect carglumic acid and Carbaglu?
The core active ingredient is an established chemical compound, which reduces the likelihood that the original composition-of-matter patent provides long-term exclusivity in the United States. Commercial protection has instead depended on orphan-drug exclusivity, regulatory approval, formulation know-how, manufacturing controls, trademarks, and any later-issued formulation or use patents.
The FDA Orange Book identifies patents and regulatory exclusivity associated with approved products when applicable. Carbaglu’s relevant regulatory record is tied to NDA 022562. Patent listings can change as products, patent certifications, and listed claims are updated. [5]
What formulations are protected by Carbaglu?
The commercial formulation has two practical elements:
- A 200 mg tablet designed for oral administration.
- A tablet-based oral suspension prepared with water for patients who require liquid administration.
The oral suspension pathway creates technical and regulatory barriers beyond simple active-ingredient replication. A competitor must demonstrate pharmaceutical equivalence, product stability, dosing accuracy, dissolution performance, and appropriate labeling. Pediatric usability and administration instructions can also affect substitution in practice.
Formulation protection is commercially relevant even when the active ingredient itself is old. A generic that matches the tablet but does not offer an equivalent or approved suspension may compete unevenly across patient segments.
When does carglumic acid lose exclusivity?
Carglumic acid has no biosimilar exclusivity issue because it is a small molecule. The key questions are generic approval, patent listings, orphan-drug exclusivity, and market authorization by formulation.
US orphan-drug exclusivity generally lasts seven years from approval for the approved indication. It prevents FDA approval of the same drug for the same indication during the exclusivity period, subject to statutory exceptions. It does not create a perpetual barrier against all carglumic acid products or against every indication. [6]
The initial US approval date for Carbaglu was March 18, 2010. The original seven-year orphan period therefore would have run from 2010 into 2017 for the initial indication, subject to the precise approved indication and FDA exclusivity record. Later indication expansions may receive separate exclusivity if the statutory requirements are met. [1, 6]
The practical exclusivity position is now more dependent on patents, FDA approval status, generic filings, formulation differences, and commercial execution than on the original orphan period.
Are there Paragraph IV challenges to Carbaglu?
A Paragraph IV challenge alleges that a listed patent is invalid, unenforceable, or not infringed. The filing can trigger patent litigation and, in many cases, a 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory conditions. [7]
The commercial significance of a Paragraph IV challenge depends on:
- The number and scope of Orange Book-listed patents.
- The asserted patent’s expiration date.
- Whether the generic seeks approval for the same formulation.
- Whether the sponsor sues within the statutory period.
- Whether the parties settle before approval.
- Whether the generic can launch “at risk.”
Publicly available product information does not establish a broad, durable patent thicket comparable to those surrounding many complex oral drugs. The more material barriers are likely to involve regulatory equivalence, formulation performance, manufacturing reliability, and specialist-market access.
What would a generic launch do to Carbaglu revenue?
A first generic would likely produce a sharper price effect in maintenance therapy than in emergency treatment. Hospitals and specialty pharmacies may substitute rapidly where formularies permit. Physicians may continue using the branded product for patients with established dosing protocols, liquid-administration needs, or reimbursement arrangements.
Potential launch scenarios include:
| Scenario |
Likely effect |
| No approved generic |
Brand retains price and volume control |
| One generic entrant |
Moderate price reduction; limited initial substitution |
| Multiple tablet generics |
Significant tablet-price erosion |
| Tablet-only competition |
Partial erosion; suspension retains differentiation |
| Tablet and suspension competition |
Broader substitution and stronger net-price pressure |
| Authorized generic or brand discounting |
Slower market-share loss but lower branded net price |
Which companies compete with carglumic acid?
Carglumic acid competes within a treatment pathway rather than against a single direct substitute.
Pharmacologic competitors
Relevant alternatives include:
- Sodium phenylbutyrate.
- Glycerol phenylbutyrate, marketed as Ravicti.
- Sodium benzoate, often used in acute metabolic management.
- Combination regimens administered in metabolic centers.
These products do not replicate carglumic acid’s mechanism. They reduce nitrogen burden through alternative metabolic pathways and may be used sequentially or in combination.
Non-drug competitors
Other interventions include protein restriction, intravenous glucose and lipids during crises, hemodialysis or hemofiltration, and liver transplantation in selected patients. The treatment decision depends on the underlying genetic disorder, ammonia level, patient age, clinical severity, and recurrence risk.
For organic acidemias, carglumic acid may be used alongside emergency protocols and dietary management. Its competitive position is strongest when rapid ammonia reduction is required and when clinicians seek a targeted intervention that addresses impaired endogenous N-acetylglutamate activity.
How strong is the carglumic acid patent estate?
The commercial IP position is moderate rather than exceptionally strong.
Strengths
- Orphan-disease specialization creates high clinical and regulatory know-how.
- The brand has long-standing recognition among metabolic specialists.
- Pediatric suspension use adds formulation complexity.
- Manufacturing quality and supply continuity matter in emergency treatment.
- Switching patients during acute-care episodes carries operational and clinical friction.
Weaknesses
- The active ingredient is an established small molecule.
- The initial US orphan exclusivity period has expired.
- The patient population is too small to support a large patent-litigation budget for every jurisdiction.
- Generic applicants can target tablet formulations if listed patent barriers are limited.
- Alternative metabolic therapies reduce dependence on one product.
The strongest defensibility is therefore likely to come from formulation execution, regulatory history, physician familiarity, distribution, and reliable availability rather than from broad composition-of-matter exclusivity.
What is the Orange Book status of Carbaglu?
Carbaglu is associated with FDA NDA 022562. The Orange Book is the controlling source for current patent listings, exclusivity codes, therapeutic equivalence evaluations, and approved dosage forms. [5]
For commercial diligence, the critical distinctions are:
- Whether a patent is listed against the tablet, suspension, or both.
- Whether the generic application references the same dosage form.
- Whether the FDA has assigned a therapeutic-equivalence rating.
- Whether exclusivity attaches to the indication or formulation.
- Whether a generic applicant has submitted a Paragraph IV certification.
An Orange Book listing does not automatically establish that a patent will withstand litigation. It identifies patents that an applicant must address in its abbreviated new drug application.
What licensing deals affect carglumic acid?
Recordati’s rare-disease platform includes products obtained through acquisitions, licensing, and regional commercialization agreements. Public company materials generally discuss the rare-disease portfolio at segment level rather than disclosing a stand-alone Carbaglu royalty stream or transfer-price structure. [3]
The key licensing risks are:
- Territory-specific rights.
- Change-of-control provisions.
- Royalty obligations.
- Manufacturing dependence on a third party.
- Rights to new formulations or indications.
- Responsibility for post-approval regulatory work.
Without a separately disclosed Carbaglu agreement and product-level accounting, licensing cannot be treated as a precise determinant of product margin.
What manufacturing and geographic barriers affect the market?
Carglumic acid manufacturing is less technically complex than biologics manufacturing, but supply reliability is commercially important because treatment may be urgent. A sponsor must maintain active-pharmaceutical-ingredient quality, tablet uniformity, stability, packaging, and suspension performance.
Geographic market dynamics differ:
| Region |
Commercial characteristics |
| United States |
Orphan pricing, specialty distribution, FDA generic pathway |
| European Union |
National reimbursement decisions and broader historical indication coverage |
| United Kingdom |
NHS reimbursement and specialist-center control |
| Japan |
Local regulatory requirements and rare-disease reimbursement |
| Emerging markets |
Lower prices, limited diagnosis, variable metabolic infrastructure |
The highest-value markets are those with established metabolic centers, reimbursement for orphan drugs, newborn screening, and reliable specialty distribution. In lower-income markets, diagnosis and affordability can be larger constraints than patent protection.
What generic entry risks exist for carglumic acid?
Generic entry risk is real but may be uneven by indication and formulation. The first approved generic could reduce price while expanding access, especially for chronic maintenance use. Brand retention may remain stronger in emergency settings, pediatric liquid administration, and cases where physicians prioritize continuity of supply.
The likely revenue sequence is:
- Stable branded demand before generic approval.
- Price concessions or contracting when an ANDA approaches approval.
- Initial share loss concentrated in price-sensitive maintenance patients.
- Larger erosion if multiple generics enter.
- Residual brand demand in complex formulations and specialist channels.
A generic launch may expand total treated volume while reducing branded revenue. That distinction matters when assessing market growth.
Key Takeaways
- Carglumic acid is an ultra-rare metabolic-disease product with high value per patient and limited absolute volume.
- Carbaglu is the principal branded product and is associated with Recordati Rare Diseases and FDA NDA 022562.
- Public financial reports do not usually disclose Carbaglu revenue separately.
- The original US orphan exclusivity period began with the March 18, 2010 approval and has expired for the initial indication.
- Current commercial protection depends on patents, formulation differences, regulatory barriers, manufacturing reliability, and specialist adoption.
- Generic risk is greater for chronic tablet therapy than for emergency use or suspension-dependent patients.
- Biosimilar risk does not apply because carglumic acid is a small molecule.
- The main competitive alternatives are nitrogen scavengers, dietary therapy, dialysis, and transplantation.
- The most defensible commercial assets are formulation execution, clinical familiarity, reimbursement access, and supply continuity.
FAQs About Carglumic Acid Market and Patents
Is carglumic acid the same as Carbaglu?
Carglumic acid is the active ingredient. Carbaglu is the branded product name used by the originator or commercial sponsor.
Is carglumic acid a biologic drug?
No. Carglumic acid is a chemically synthesized small molecule, so it follows the generic-drug pathway rather than the biosimilar pathway.
Does Carbaglu have FDA orphan-drug exclusivity today?
The initial seven-year US orphan exclusivity period associated with the 2010 approval has expired. Any later indication-specific exclusivity must be evaluated separately in the FDA regulatory record.
What is the largest commercial risk to Carbaglu?
The largest risk is generic competition that reaches both tablet and oral-suspension formulations, coupled with payer-driven substitution in chronic maintenance treatment.
Can carglumic acid sales grow after generic entry?
Total patient access can grow after generic entry, but branded revenue and net price would generally face pressure. Growth would depend on diagnosis expansion, broader reimbursement, and treatment adoption in organic acidemias.
References
-
U.S. Food and Drug Administration. (2010). Carbaglu (carglumic acid) prescribing information. FDA.
-
European Medicines Agency. (n.d.). Carbaglu: EPAR product information. EMA.
-
Recordati S.p.A. (2024). Annual report and consolidated financial statements. Recordati.
-
Centers for Disease Control and Prevention. (n.d.). Recommended uniform screening panel for newborn screening. CDC.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
-
U.S. Food and Drug Administration. (n.d.). Orphan drug designation and exclusivity. FDA.
-
U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. FDA.
